Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Phio Pharmaceuticals Corp (PHIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PHIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -80.02% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.02M USD | Price to earnings Ratio - | 1Y Target Price 36 |
Price to earnings Ratio - | 1Y Target Price 36 | ||
Volume (30-day avg) 113508 | Beta 1.47 | 52 Weeks Range 1.22 - 9.79 | Updated Date 03/30/2025 |
52 Weeks Range 1.22 - 9.79 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.81 |
Earnings Date
Report Date 2025-03-31 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -61.07% | Return on Equity (TTM) -126.86% |
Valuation
Trailing PE - | Forward PE 0.35 | Enterprise Value -2149561 | Price to Sales(TTM) 48.01 |
Enterprise Value -2149561 | Price to Sales(TTM) 48.01 | ||
Enterprise Value to Revenue 172.2 | Enterprise Value to EBITDA 0.61 | Shares Outstanding 860721 | Shares Floating 547832 |
Shares Outstanding 860721 | Shares Floating 547832 | ||
Percent Insiders 5.89 | Percent Institutions 2.07 |
Analyst Ratings
Rating 4 | Target Price 72 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Phio Pharmaceuticals Corp
Company Overview
History and Background
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing novel therapies to treat cancer and immune-related diseases through its proprietary self-delivering RNAi (sd-rxRNAu00ae) technology platform. The company, formerly known as RXi Pharmaceuticals, was founded in 2011, evolved from a discovery research company focused on RNAi to a clinical-stage biotechnology company focusing on immuno-oncology.
Core Business Areas
- Immuno-Oncology: Development of sd-rxRNA therapeutics for immune cells in the tumor microenvironment. These therapies aim to enhance anti-tumor immunity and improve patient outcomes.
Leadership and Structure
Phio Pharmaceuticals Corp's leadership team includes a CEO, CFO, Chief Scientific Officer, and a board of directors. The organizational structure comprises research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- PH-762: An investigational sd-rxRNA compound designed to reduce TIGIT expression to enhance anti-tumor immunity. Currently in preclinical development. Competitors developing TIGIT inhibitors include Roche (RG6058), Gilead (domvanalimab), and Arcus Biosciences.
- PH-804: An investigational sd-rxRNA compound designed to reduce PD-1 expression to enhance anti-tumor immunity. Currently in preclinical development. Competitors developing PD-1 inhibitors include Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and Regeneron (Libtayo).
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing rapid growth, driven by the increasing prevalence of cancer and advancements in understanding the role of the immune system in fighting cancer. RNAi therapeutics represent a promising approach in this field.
Positioning
Phio Pharmaceuticals Corp is positioned as a company developing novel RNAi-based therapeutics to address unmet needs in immuno-oncology. Their sd-rxRNA platform provides a competitive advantage in delivery and target specificity.
Total Addressable Market (TAM)
The total addressable market for immuno-oncology therapies is estimated to be in the tens of billions of dollars. Phio is targeting specific pathways like TIGIT and PD-1, positioning them to capture a segment of this large market if their therapies are successful.
Upturn SWOT Analysis
Strengths
- Proprietary sd-rxRNA technology platform
- Focus on immuno-oncology
- Experienced management team
- Targeting of clinically validated pathways (TIGIT and PD-1)
Weaknesses
- Limited financial resources
- Early stage clinical development
- Dependence on a single technology platform
- Small Market Capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of sd-rxRNA platform to other therapeutic areas
- Positive clinical trial results
- Grant Funding
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- IP challenges
- Financial Market Conditions
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
- GILD
Competitive Landscape
Phio Pharmaceuticals Corp. faces significant competition from larger, more established pharmaceutical companies with greater resources. Their competitive advantage lies in their novel RNAi technology and targeted approach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by research and development progress and fluctuations in share price based on preclinical and early clinical data.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and potential partnerships.
Recent Initiatives: Recent initiatives include advancing PH-762 and PH-804 through preclinical development and exploring potential collaborations.
Summary
Phio Pharmaceuticals is a small biotechnology company with a promising RNAi platform targeting immuno-oncology. Its success hinges on preclinical and clinical data in its PH-762 and PH-804 programs. The company faces significant challenges related to funding and competition. Partnering may be crucial to drive growth. Clinical Trial results will drive the company forward.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Financial news sources
- Industry reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phio Pharmaceuticals Corp
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 2012-05-10 | President, CEO & Chairman Mr. Robert J. Bitterman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://phiopharma.com |
Full time employees 8 | Website https://phiopharma.com | ||
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.